CERO THERAPEUTICS HOLDINGS I(NASDAQ:CERO) stock News

CERO Latest News, Press Relases and Analysis

All

Press Releases

16 days ago - By: Chartmill - Mentions: NEON SXTC SNTG PRSO ...

The trading volume of these stocks is deviating from the norm in today's session.

2 days ago - By: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Progresses Phase 1 CER-1236 AML Trial with Dosing of Third Patient in Initial Dose Cohort

2 days ago - By: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Progresses Phase 1 CER-1236 AML Trial with Dosing of Third Patient in Initial Dose Cohort

15 days ago - By: Benzinga - Mentions: SMMT RENB

Top 3 Health Care Stocks You'll Regret Missing In Q3

15 days ago - By: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Receives Notice of Allowance from U.S. Patent and Trade Office on Composition of Matter and Method of Use for CER-1236 in Cancer with Expected Protection Through 2041

15 days ago - By: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Receives Notice of Allowance from U.S. Patent and Trade Office on Composition of Matter and Method of Use for CER-1236 in Cancer with Expected Protection Through 2041

16 days ago - By: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Announces Dose Intensification in Phase 1 Study of CER-1236 in Acute Myeloid Leukemia

16 days ago - By: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Announces Dose Intensification in Phase 1 Study of CER-1236 in Acute Myeloid Leukemia

19 days ago - By: Stocktwits

CERo Therapeutics Gets Fast Track Designation For Experimental Cancer Drug, But Stock Tumbles – Here’s What Happened

19 days ago - By: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Receives FDA Fast Track Designation for CER-1236 in Acute Myeloid Leukemia (AML)

19 days ago - By: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Receives FDA Fast Track Designation for CER-1236 in Acute Myeloid Leukemia (AML)

2 months ago - By: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Doses Second Acute Myeloid Leukemia Patient with CER-1236

2 months ago - By: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Doses Second Acute Myeloid Leukemia Patient with CER-1236

3 months ago - By: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236

3 months ago - By: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236

3 months ago - By: Stocktwits

Cero Therapeutics Rockets On FDA Orphan Drug Status For Blood Cancer Drug; Retail Bulls Feel Stock 'Still Has A Few Pumps Left'

3 months ago - By: Benzinga - Mentions: SEDG RUN PCSA ACXP ...

US Stocks Lower; Retail Sales Decline In May

3 months ago - By: CERo Therapeutics Holdings, Inc.

CERO THERAPEUTICS HOLDINGS I (CERO) Stock News

CERO Latest News, Press Relases and Analysis

The trading volume of these stocks is deviating from the norm in today's session.

CERo Therapeutics Progresses Phase 1 CER-1236 AML Trial with Dosing of Third Patient in Initial Dose Cohort

CERo Therapeutics Progresses Phase 1 CER-1236 AML Trial with Dosing of Third Patient in Initial Dose Cohort

Top 3 Health Care Stocks You'll Regret Missing In Q3

CERo Therapeutics Receives Notice of Allowance from U.S. Patent and Trade Office on Composition of Matter and Method of Use for CER-1236 in Cancer with Expected Protection Through 2041

CERo Therapeutics Receives Notice of Allowance from U.S. Patent and Trade Office on Composition of Matter and Method of Use for CER-1236 in Cancer with Expected Protection Through 2041

CERo Therapeutics Announces Dose Intensification in Phase 1 Study of CER-1236 in Acute Myeloid Leukemia

CERo Therapeutics Announces Dose Intensification in Phase 1 Study of CER-1236 in Acute Myeloid Leukemia

CERo Therapeutics Gets Fast Track Designation For Experimental Cancer Drug, But Stock Tumbles – Here’s What Happened

CERo Therapeutics Receives FDA Fast Track Designation for CER-1236 in Acute Myeloid Leukemia (AML)

CERo Therapeutics Receives FDA Fast Track Designation for CER-1236 in Acute Myeloid Leukemia (AML)

CERo Therapeutics Doses Second Acute Myeloid Leukemia Patient with CER-1236

CERo Therapeutics Doses Second Acute Myeloid Leukemia Patient with CER-1236

CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236

CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236

Cero Therapeutics Rockets On FDA Orphan Drug Status For Blood Cancer Drug; Retail Bulls Feel Stock 'Still Has A Few Pumps Left'

US Stocks Lower; Retail Sales Decline In May

CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug Designation Granted to CER-1236 for the Treatment of Acute Myeloid Leukemia (AML)